Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Gulliver

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Practical Neurology|June 26, 2017
Hepatitis E virus and neurological disordersBrendan N Mclean, James Gulliver, Harry R Dalton
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Practical Neurology|June 26, 2017
Hepatitis E virus and neurological disordersBrendan N Mclean, James Gulliver, Harry R Dalton
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 1